These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26365140)

  • 1. Treatment Options in Alzheimer´s Disease: The GABA Story.
    Solas M; Puerta E; Ramirez MJ
    Curr Pharm Des; 2015; 21(34):4960-71. PubMed ID: 26365140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical basis for symptomatic treatment of Alzheimer's disease.
    Francis PT; Ramírez MJ; Lai MK
    Neuropharmacology; 2010; 59(4-5):221-9. PubMed ID: 20156462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.
    Govindpani K; Calvo-Flores Guzmán B; Vinnakota C; Waldvogel HJ; Faull RL; Kwakowsky A
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28825683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease.
    Garcia-Alloza M; Tsang SW; Gil-Bea FJ; Francis PT; Lai MK; Marcos B; Chen CP; Ramirez MJ
    Neurobiol Aging; 2006 Aug; 27(8):1110-7. PubMed ID: 15996794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.
    Ramirez MJ; Lai MK; Tordera RM; Francis PT
    Drugs; 2014 May; 74(7):729-36. PubMed ID: 24802806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unsupervised excitation: GABAergic dysfunctions in Alzheimer's disease.
    Ambrad Giovannetti E; Fuhrmann M
    Brain Res; 2019 Mar; 1707():216-226. PubMed ID: 30503351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geniposide ameliorates cognitive deficits by attenuating the cholinergic defect and amyloidosis in middle-aged Alzheimer model mice.
    Zhao C; Zhang H; Li H; Lv C; Liu X; Li Z; Xin W; Wang Y; Zhang W
    Neuropharmacology; 2017 Apr; 116():18-29. PubMed ID: 27940040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of Alzheimer's disease].
    Bombois S; Lebert F; Vellas B; Pasquier F
    Rev Prat; 2005 Nov; 55(17):1913-9. PubMed ID: 16396232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia.
    Lanctôt KL; Herrmann N; Mazzotta P; Khan LR; Ingber N
    Can J Psychiatry; 2004 Jul; 49(7):439-53. PubMed ID: 15362248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
    Hampel H; Mesulam MM; Cuello AC; Farlow MR; Giacobini E; Grossberg GT; Khachaturian AS; Vergallo A; Cavedo E; Snyder PJ; Khachaturian ZS
    Brain; 2018 Jul; 141(7):1917-1933. PubMed ID: 29850777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A second wind for the cholinergic system in Alzheimer's therapy.
    Douchamps V; Mathis C
    Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):112-123. PubMed ID: 28240674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral correlates of GABAergic disruption in Alzheimer's disease.
    Lanctôt KL; Herrmann N; Rothenburg L; Eryavec G
    Int Psychogeriatr; 2007 Feb; 19(1):151-8. PubMed ID: 16870038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials.
    Mohs RC
    Genes Brain Behav; 2005 Apr; 4(3):129-33. PubMed ID: 15810901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease.
    Cheng YJ; Lin CH; Lane HY
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.
    Lawrence AD; Sahakian BJ
    Neurochem Res; 1998 May; 23(5):787-94. PubMed ID: 9566619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
    Brousseau G; Rourke BP; Burke B
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.